The ‘How much are you raising?’ question is a common and important component of investor Q&A. Seasoned founders have a particular way of answering this question. In this Dreamit Dose, Managing Director Adam Dakin presents his view on the right way to answer it after hearing hundreds, if not thousands, of founder pitches.

The "What’s your valuation?" question is a common component of investor Q/A. You need to be aware of and ready for this tough question from investors. In this Dreamit Dose, Managing Director Adam Dakin reveals the right approach on how to answer the valuation question when pitching VCs.

The venture capital screening call is an important step to get right in due diligence. To get to partners, often you’ll have to go through the associate first. In this Dreamit Dose, associates Alana Hill and Elliot Levy offer five things they wish founders knew after screening over 1,000 startups in the last year.

Dreamit Ventures and MedCityNews teamed up to get a pulse on the current appetite for innovation at large health systems across the United States. The survey data tapped senior innovation leaders, 85% of whom came from health systems with over 1,000 beds.

Speaking to investors can require a language of its own. Word choice is important and even the smallest detail can make or break your startup pitch. Adam Dakin, Managing Director of Dreamit Healthtech, sees founders make the same common pitch mistakes over and over. Luckily, he’s a pro when it comes to pitching investors and distills the advice so it’s easy to avoid. In this Dreamit Dose, Adam dives into the language of the pitch and flags three common mistakes you’ll want to avoid.

Today, Infermedica (HT ‘18) announced a $10M Series A financing round for their AI-driven platform that helps insurance, telemedicine companies, and health systems increase efficiency through fast, digital symptom-checks. The platform has nearly 60 B2B partners across 30 countries, including Microsoft, Allianz, Global Excel, Sana Kliniken, and Médis, and has performed more than 6 million health checks globally. Read here.

TrekIT Health (HT- ‘18) announced closing $1M in additional seed financing. TrekIt’s technology is a HIPAA compliant and secure, real-time workspace for synthesizing information across EHRs and care teams. Clinicians love TrekIT because of its intuitive and predictive interface which serves as a cure for disjointed information systems and a replacement for paper task lists. Read more.

Ruvna, a safety and communication platform for school systems, is releasing a new product this fall providing COVID-19 screening, tracking, and compliance for schools and districts called Ruvna Health. Learn more about the solution here.

Last week, EnsoData (Healthtech - Spring 2019) announced a $9 million Series A financing round led by Venture Investors and Zetta Venture Partners, with participation from Dreamit Ventures. Their platform transforms billions of waveform data points collected from sensors in medical devices and wearables into an easy-to-read report, so clinicians can make faster, more accurate diagnoses.

Good founders know the importance of nailing their product demo. While many demo, few excel at it. In this #DreamitDose, Managing Partner Steve Barsh gives founders a simple framework to crush your demo. Along the way, Steve reveals pro tips like how to layer in traction and provides an example of a truly compelling use case.

Wellth, a platform designed to improve treatment adherence using behavioral economics, announced the closing of their $10M Series A round, co-led by yabeo and Boehringer Ingelheim Venture Fund (BIVF). Wellth graduated from Dreamit’s Healthtech program in 2016.

Net Health has acquired Tissue Analytics, a pioneering developer of automated mobile wound and skin imaging and predictive analytics solutions. The Baltimore-based startup graduated from Dreamit’s Healthtech program in 2014.

Will the pandemic change healthcare? Earlier this month, Adam Dakin, Managing Director of Dreamit Healthtech, joined Phase2 Health to share his insight on the topic. Read to explore shifts in venture investment, healthtech trends, and what the world will look like after Covid-19.

More than 15 Dreamit Healthtech companies have products that are helping to mitigate the spread of COVID-19. These companies are actively deploying COVID-19 solutions in hospitals and healthcare systems. Read on to explore solutions by use case.

NarrativeDX (Healthtech - Fall 2014) is the latest win for the Dreamit portfolio. Today, the company announced that it is being acquired by health care performance improvement pioneer Press Ganey.

Telehealth is having a moment right now. With global psyche engrossed in COVID-19 press, this could be telehealth's 'put-me-in-coach' moment. Read on to dive deeper.

Getting investors excited about your product is a critical part of raising capital. But founders are often so consumed with talking metrics, milestones achieved, or the capital they need that they sometimes forget to talk about their overarching vision for their startups. In this article, we provide some strategies for selling investors on your vision for your startup.

NeuroFlow is a platform for getting patients with behavioral health issues better by supporting clinical teams with collaborative and measurement-based tools in all care settings. The company announces a $7.5 million Series A financing round led by San Francisco-based Builders VC.

A thoughtful strategic approach to equity structure and allocation is critical for all startups. Yet, over and over again, startups often make avoidable mistakes that can have catastrophic downstream effects. In this #DreamitLive, Managing Director Adam Dakin speaks with Geoff Starr, Partner at Cooley, about five common mistakes and how to avoid them. Geoff has developed great pattern recognition, having counseled hundreds of startups on raising capital and allocating equity.

Fundraising is hard, and it’s critical to have a game-plan and process for raising capital. In this episode, Steve Barsh discusses some strategies that founders can use to close a new round of funding. He talks about how to create momentum, revenue metrics you’ll need to show for seed and Series A funding, what a typical timeline looks like, how to determine the amount of capital you need to raise, and more.